Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1603-1607

  Li, Zhengguang ^a   Wu, Changping ^a   Wu, Jun ^a   Ji, Mei ^a   Shi, Liangrong ^a   Jiang, Jingting ^a   Xu, Bin ^a   Yuan, Jinjin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cisplatin; Deguelin; Gastric cancer; Synergism

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; DEGUELIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOREACTIVITY; ISOBOLOGRAM ANALYSIS; PROTEIN EXPRESSION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84915782116     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2368     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Songun I, Putter H, Kranenbarg EM, Sasako M and van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: 439-449, 2010.
3. Jain VK, Cunningham D and Chau I: Preoperative and postoperative chemotherapy for gastric cancer. Surg Oncol Clin N Am 21: 99-112, 2012.
4. Pasini F, Fraccon AP and DE Manzoni G: The role of chemotherapy in metastatic gastric cancer. Anticancer Res 31: 3543-3554, 2011.
5. Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34: 1522-1534, 1998.
6. Monneret C: Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr 69: 286-295, 2011.
7. Kang YK, Kang WK, Shin DB, et al: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20: 666-673, 2009.
8. Koizumi W, Tanabe S, Saigenji K, et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
9. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
10. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
11. Rennicke A, Voigt W, Mueller T, et al: Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Anticancer Res 25: 1147-1155, 2005.
12. Timmer-Bosscha H, Mulder NH and de Vries EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 66: 227-238, 1992.
13. Chun KH, Kosmeder JW II, Sun S, et al: Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95: 291-302, 2003.
14. Lee HY, Oh SH, Woo JK, et al: Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97: 1695-1699, 2005.
15. Murillo G, Salti GI, Kosmeder JW II, Pezzuto JM and Mehta RG: Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer 38: 2446-2454, 2002.
16. Ji BC, Yu CC, Yang ST, et al: Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncol Rep 27: 959-964, 2012.
17. Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004.
18. Choi MK and Kim DD: Platinum transporters and drug resistance. Arch Pharm Res 29: 1067-1073, 2006.
19. Howell SB, Safaei R, Larson CA and Sailor MJ: Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77: 887-894, 2010.
20. Olaussen KA, Mountzios G and Soria JC: ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13: 284-289, 2007.
21. Saldivar JS, Wu X, Follen M and Gershenson D: Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol 107 (Suppl 1): S56-S71, 2007.
22. Wernyj RP and Morin PJ: Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 7: 227-232, 2004.
23. Hou W, Chen L, Yang G, et al: Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res 22: 1125-1132, 2008.
24. Choi KS, Jun JK, Park EC, et al: Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One 7: e50041, 2012.
25. Hainsworth JD, Johnson DH and Greco FA: Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 10: 912-922, 1992.
26. Ohtsu A, Shimada Y, Yoshida S, et al: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A: 2091-2093, 1994.
27. Fuertes MA, Castilla J, Alonso C and Pérez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10: 257-266, 2003.
28. Brabec V: DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucleic Acid Res Mol Biol 71: 1-68, 2002.
29. Brabec V and Kasparkova J: Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8: 131-146, 2005.
30. Bortul R, Tazzari PL, Billi AM, et al: Deguelin, a PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129: 677-686, 2005.